Oculis (OCS) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
27 Jul, 2026Strategic focus and pipeline overview
Two late-stage candidates target significant unmet needs in neuro-ophthalmology and ophthalmology, with global market opportunities and strong financials supporting development through 2029.
Privosegtor is a neuroprotective peptoid with FDA Breakthrough Therapy and EMA PRIME designations for optic neuritis, and potential expansion into NAION, MS relapses, and broader neuro-axonal diseases.
Licaminlimab is a topical anti-TNFα biologic for dry eye disease, advancing a precision medicine approach based on TNFR1 genotype, with topline results from the pivotal PREDICT-1 trial expected around year-end 2026.
Privosegtor clinical and preclinical highlights
Demonstrated neuroprotection in preclinical models, preserving neurons and axons in glaucoma, MS, and optic neuritis.
Phase 2 ACUITY trial in optic neuritis showed significant and sustained improvements in low-contrast visual acuity (LCVA), with robust subgroup effects and anatomical preservation of retinal layers.
Biological markers, including reduced neurofilament levels, support neuroprotective effects.
Safety profile in Phase 2 showed no drug-related serious adverse events or discontinuations.
Market potential and development milestones
Privosegtor targets over 60,000 acute optic neuropathy cases annually in the US, with a potential market exceeding $7B based on rare disease pricing analogs.
PIONEER-1 registrational trial in optic neuritis is underway, with two additional pivotal trials (PIONEER-2 and PIONEER-3) and an IND for MS relapses planned for 2026–2027.
Privosegtor could become the first approved neuroprotective therapy for optic neuropathies.
Latest events from Oculis
- Privosegtor advances neuroprotection while licaminlimab tests biomarker-guided dry-eye care.OCS
Stifel 2026 Healthcare Conference 2026 - PREDICT-1 readout nears as privosegtor advances across neuroprotection indications.OCS
3rd Annual Guggenheim Healthcare Innovation Conference - Late-stage trials advance as $252.0M in cash supports runway into 2H 2029.OCS
Q3 2026 - ACUITY signals support a registrational optic neuritis program for privosegtor.OCS
Euretina Innovation Spotlight (EIS) 2026 Presentation - TNFR1-guided dry-eye development targets greater benefit in biomarker-positive patients.OCS
Study presentation - Phase III programs in dry eye and optic neuritis advance, with MS and NAION expansion planned.OCS
2026 Global Healthcare Conference - Precision medicine and targeted trials drive clinical and commercial strategy, with strong funding.OCS
H.C. Wainwright 28th Annual Global Investment Conference - Privosegtor and Licaminlimab trials advance, with strong cash reserves supporting long-term growth.OCS
Q2 2026 - Positive clinical results and precision medicine advances set the stage for major milestones in 2024–2025.OCS
H.C. Wainwright 26th Annual Global Investment Conference